Sana Biotechnology, Inc. announced two additions to its senior leadership team. Ed Rebar, Ph.D., joins the company as Chief Technology Officer and Terry Fry, M.D. joins as SVP, Head of T Cell Therapeutics. Dr. Rebar has over 20 years of experience in developing novel gene editing and cell engineering technologies for therapeutic use. As Sana's Chief Technology Officer, he is responsible for developing genome editing, gene regulation, cell engineering, analytical genomics and computational biology functions. Prior to joining Sana, Dr. Rebar worked at Sangamo Therapeutics to develop the company's zinc finger protein platform for therapeutic applications, most recently as the company's Chief Technology Officer. His work included the development of nucleases and transcription factors for applications in oncology, HIV, hemoglobinopathies, rare diseases and cardiovascular disease, as well as heading the research team that engineered the first TALE-nucleases for high efficiency gene editing. Dr. Fry is one of the pioneers in developing CAR T therapies for treatment of cancer. In his role as Head of T Cell Therapeutics, he will lead Sana's T cell therapeutic programs, including separate platforms focused on in vivo generation of CAR T cells and allogeneic CAR T cells, with the goal of developing therapeutics for multiple cancers. Prior to joining Sana, Dr. Fry was a Professor of Pediatrics, Hematology, and Immunology as well as Director of Cancer Immunotherapy at the University of Colorado School of Medicine and Children's Hospital Colorado, where he developed several CAR T therapies entering the clinic for hematologic malignancies.